Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$166.51 USD
-3.32 (-1.95%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $166.38 -0.13 (-0.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Return on Equity (TTM)
Ligand Pharmaceuticals Incorporated's return on equity, or ROE, is -9.21% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that LGND has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LGND 166.51 -3.32(-1.95%)
Will LGND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LGND
Is LGND gathering momentum? Bollinger Band Squeeze shows up after dropping 1.95%
LGND makes New 52 Week Closing High on September 18
LGND falls 0.5% on September 18, leaving the technical picture intact
Pocket Pivot appears for LGND after 0.44% move
LGND forms 20 Day Moving Average Support on September 15